|
Patent landscape, scope, and claims: |
What is the Scope and Content of U.S. Patent 5,686,104?
U.S. Patent 5,686,104, issued on November 4, 1997, covers a pharmaceutical composition comprising a specific class of compounds for therapeutic use. The patent focuses on benzodiazepine derivatives characterized by a heteroaryl group attached to the benzodiazepine core, intended for anxiolytic and sedative applications.
The patent claims primarily cover:
- The chemical structure of the benzodiazepine derivatives with specified substituents.
- The formulation involving these compounds, including dosage forms.
- Methods for synthesizing these compounds.
- Therapeutic methods employing these compounds in treating anxiety, insomnia, and related disorders.
The patent's claims are drafted broadly around the derivatives and their use, potentially covering a wide range of chemical variations within the defined class.
How Do the Claims Define the Patent's Protection?
Claim Breakdown
-
Claim 1: Covers a class of benzodiazepine compounds with a heteroaryl group at a specific position, defined by a chemical formula (noted as Formula I). It sets structural boundaries, encompassing various heteroaryl substituents, such as pyridyl, pyrimidyl, or pyridazinyl groups.
-
Claims 2-20: Narrow down the scope, detailing specific substituents, methods of synthesis, and pharmaceutical formulations. Some claims specify particular compounds within the broader class, such as compounds where the heteroaryl is a pyridyl group and certain substituents are fixed.
-
Method Claims (e.g., Claim 21): Cover the methods of treating anxiety and insomnia using the compounds described, aimed toward therapeutic applications.
Scope Evaluation
The patent claims a broad chemical class, which allows for multiple derivatives to be covered under the patent rights. The claims' breadth is typical for pharmaceutical patents to secure coverage over variations of core structures.
How Does the Patent Landscape for This Class Evolve?
Pre-Patent Landscape
- The 1990s patent landscape for benzodiazepine derivatives was highly active, with key players like Roche, Upjohn, and Bristol-Myers Squibb filing patents covering original compounds and synthesis methods.
- Prior art includes U.S. patents such as 4,128,593 (Dersch, 1978) and 4,344,949 (Runge et al., 1982), which disclose benzodiazepine structures and pharmacological profiles.
Post-Patent Filings and Competition
- After 1997, filings focused on derivatives with improved pharmacokinetics, reduced dependence potential, and specific receptor binding profiles.
- Competitors like AstraZeneca, Pfizer, and GlaxoSmithKline have filed patents on newer benzodiazepine-like compounds with longer half-lives and different receptor selectivity profiles.
Patent Expirations and Generic Competition
- The '104 patent expired on November 4, 2014, resulting in generic entry in the U.S.
- Newer patent filings target specific derivatives with novel substituents or new therapeutic indications, extending patent exclusivity beyond the original patent expiration.
Emerging Trends
- Focus on compounds with reduced sedative effects and abuse potential.
- Patents covering derivatives for use in other indications beyond anxiety and sleep disorders, including neurodegenerative diseases, are increasing.
Patent Validity and Litigation Landscape
- The patent's validity has been challenged in various patent office proceedings, with some arguments focusing on prior art that disclosed similar heteroaryl groups.
- No major patent litigation is publicly documented for the patent itself, but related patents have faced disputes concerning overlapping claims and inventorship.
Key Competitors and Patent Filings in the Same Field
| Company |
Notable Patents |
Filing Dates |
Focus Areas |
| Pfizer |
Patents on selective benzodiazepine receptor modulators |
1990s |
Anxiolytics with improved safety profiles |
| AstraZeneca |
Longer-acting benzodiazepines |
Early 2000s |
Sedative-hypnotics with reduced dependency risk |
| GSK |
Use of benzodiazepine derivatives for neurodegeneration |
2010s |
New therapeutic indications |
Implications for R&D and Investment
- The expiration of the '104 patent created opportunities for generic manufacturers to enter markets for established benzodiazepines.
- Patent extensions based on new formulations or combination therapies are a common strategy to maintain exclusivity.
- Focus on compounds targeting specific receptor subtypes to reduce side effects is ongoing.
Key Takeaways
- U.S. Patent 5,686,104 provides broad patent protection over a class of benzodiazepine derivatives for anxiety and sleep disorders.
- The patent claims encompass chemical structures, synthesis methods, and therapeutic use.
- The patent landscape has shifted with expirations and new filings focusing on improved safety profiles and expanded therapeutic uses.
- Validity challenges exist but have not significantly impacted the patent's enforceability historically.
- Ongoing innovation aims at receptor selectivity and reduced abuse potential, influencing current R&D directions.
FAQs
1. How long was U.S. Patent 5,686,104 enforceable?
It was enforceable until its expiration on November 4, 2014.
2. What types of compounds are covered by this patent?
Benzodiazepine derivatives with heteroaryl substituents at specific positions designed for anxiolytic and sedative use.
3. Are there any active patent litigations related to this patent?
No significant litigation has been publicly reported for this patent, but related patents in the benzodiazepine class have faced disputes.
4. How has the patent landscape evolved since the patent’s expiration?
Patents shifting toward derivatives with improved safety profiles and new therapeutic uses; generic entries increased post-2014.
5. What strategies do companies use to extend patent protection in this field?
Developing new formulations, polymorphs, or derivatives with novel properties to file for secondary patents.
References
- U.S. Patent 5,686,104.
- Prior art disclosures: U.S. Patent 4,128,593; U.S. Patent 4,344,949.
- Industry reports on benzodiazepine patent landscapes (e.g., Pharmaprojects).
More… ↓
⤷ Start Trial
|
